New Edition of NABCO Breast Cancer Resource List Is Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just published the 1996-1997 edition of the NABCO Breast Cancer Resource List, made possible through an educational grant from Glaxo Wellcome Inc

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just published the 1996-1997 edition of the NABCOBreast Cancer Resource List, made possible through an educationalgrant from Glaxo Wellcome Inc.

At more than 75 pages, it is NABCO's most comprehensive breastcancer resource guide to date. The booklet includes educationaland resource information for both the lay public and health careprofessionals, as well as a list of 350 breast cancer supportgroups nationwide. Many of the more than 2,000 listed publications(books, brochures, and videos) are available free or at low cost.

To obtain a copy, please send a self-addressed mailing label anda $3.00 check to NABCO, 9 East 37th Street, New York, NY 10016.Please indicate if you prefer the waiting room version markedwith the legend "Display Copy."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.